Prediction of acute GVHD following hematopoietic stem cell transplantation by using MLR-ELISPOT assay

Prediction of acute GVHD following hematopoietic stem cell transplantation by using MLR-ELISPOT assay - Prediction of acute GVHD by MLR- ELISPOT assay

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009674

Enrollment

Registered

2012-12-31

Start date

2012-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological disease for hematopoietic stem cell transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Provide signed, written informed consent. 2. Possible obtaining peripheral blood from donor and recipient before hematopoietic stem cell transplantation. 3. Patient without a serious complication except acute GVHD at collection of blood sample.

Exclusion criteria

Exclusion criteria: 1. Patient that quantity of blood sampling is regarded as a physical burden for reasons of the age or the body weight.

Design outcomes

Primary

Measure	Time frame
Correlation between donor IFN-gamma production ability to recipient and acute GVHD	—

Secondary

Measure	Time frame
Correlation between donor IL-10 production ability to recipient and acute GVHD	—

Countries

Japan

Contacts

Public ContactMasahiro Hirayama

Mie University Graduate School of Medicine Department of Pediatrics

hirayama@clin.medic.mie-u.ac.jp+81-059-232-1111

Outcome results